Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by GHP Investment Advisors Inc.

GHP Investment Advisors Inc. boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 1,681.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,065 shares of the company's stock after acquiring an additional 30,265 shares during the period. GHP Investment Advisors Inc.'s holdings in Teva Pharmaceutical Industries were worth $578,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of TEVA. New Covenant Trust Company N.A. purchased a new stake in Teva Pharmaceutical Industries during the first quarter worth $28,000. EntryPoint Capital LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $30,000. UMB Bank n.a. grew its position in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after acquiring an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA acquired a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $48,000. Finally, Byrne Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $52,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on TEVA shares. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, October 21st. UBS Group increased their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Argus raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 target price on the stock in a research note on Wednesday, July 10th. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $19.67.

Teva Pharmaceutical Industries Stock Up 2.6 %

Shares of NYSE:TEVA traded up $0.47 during trading on Monday, hitting $18.37. The company's stock had a trading volume of 3,864,521 shares, compared to its average volume of 9,329,213. The company has a market capitalization of $20.81 billion, a PE ratio of -44.80, a P/E/G ratio of 1.29 and a beta of 0.88. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. Teva Pharmaceutical Industries Limited has a fifty-two week low of $8.23 and a fifty-two week high of $19.08. The business has a 50 day moving average price of $18.01 and a two-hundred day moving average price of $16.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.16 billion during the quarter, compared to analysts' expectations of $3.99 billion. As a group, research analysts expect that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Eric A. Hughes sold 24,537 shares of the company's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the sale, the insider now directly owns 45,060 shares of the company's stock, valued at $777,285. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.